0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Neurology |

In This Issue of JAMA Neurology FREE

JAMA Neurol. 2013;70(6):679-680. doi:10.1001/jamaneurol.2013.83.
Text Size: A A A
Published online

THE NEUROGENOMICS VIEW OF NEUROLOGICAL DISEASES

Tsuji reviews high-throughput genome sequencing technologies, the availability of which is expected to revolutionize our understanding of not only hereditary neurological diseases but also sporadic neurological diseases. It will be a new era of datacentric clinical practice.

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Road map to personal genome medicine. Since the completion of the human genome sequence in 2003, the research focus in human genetics has moved to how human genome variations affect human health. Human genome variations are considered to be associated not only with hereditary diseases but also with sporadic diseases. In addition, human genome variations are also associated with differences in drug responses and adverse effects. Optimization of treatment and prevention based on personal genome information will soon be a realistic paradigm in clinical practice.

GENETIC ANALYSIS IN NEUROLOGY: THE NEXT 10 YEARS

In recent years, neurogenetics research had made some remarkable advances owing to the advent of genotyping arrays and next-generation sequencing. Pittman and Hardy review how these technological advances have changed the approaches being used to study the genetic basis of neurological disease and how the research findings will be translated into clinical utility.

UNDERSTANDING NEUROLOGICAL DISEASE MECHANISMS IN THE ERA OF EPIGENETICS

Qureshi and Mehler highlight emerging paradigms for linking epigenetic machinery and processes with neurological diseasestates.

EPIGENETIC DETERMINANTS OF HEALTHY AND DISEASED BRAIN AGING AND COGNITION

Akbarian and colleagues provide an overview of age-related changes in the brain's chromatin structures, highlight potential epigenetic drug targets for cognitive decline and age-related neurodegenerative disease, and discuss opportunities and challenges when studying epigenetic biomarkers in aging research.

AN INFLECTION POINT IN GENE DISCOVERY EFFORTS FOR NEURODEGENERATIVE DISEASES: FROM DIAGNOSES TOWARD ENDOPHENOTYPES AND THE EPIGENOME

De Jager and Bennett review the current understanding of the genetic architecture of 4 common neurodegenerative diseases and use them to highlight successful strategies for gene discovery as well as emerging strategies being deployed to address the next series of challenges in investigating the pathophysiological basis of these diseases.

A MULTICENTER STUDY OF GLUCOCEREBROSIDASE MUTATIONS IN DEMENTIA WITH LEWY BODIES

Nalls et al performed a multicenter collection of genotyping data to establish whether GBA1 mutations are a risk factor for dementia with Lewy bodies. Editorial perspective is provided by Christine Klein, MD, and Dimitri Krainc, MD, PhD.

C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSIONS IN CLINICAL ALZHEIMER DISEASE

Harms and colleagues investigated the frequency of C9orf72 repeat expansions in clinically diagnosed late-onset Alzheimer disease among families recruited for the National Institute on Aging Late-Onset Alzheimer Disease Family Study.

C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION AND GUAM AMYOTROPHIC LATERAL SCLEROSIS–PARKINSONISM-DEMENTIA COMPLEX

In a case-control series, Dombroski et al performed genotyping among Guam residents to determine whether the C9orf72 expanded repeat allele contributes to amyotrophic lateral sclerosis–parkinsonism-dementia complex in this population and to evaluate LRRK2 for mutations. Participants were screened for C9orf72 hexanucleotide repeat length. LRRK2 was screened for point mutations by DNA sequencing.

HEREDITARY ATAXIA AND SPASTIC PARAPLEGIA IN PORTUGAL: A POPULATION-BASED PREVALENCE STUDY

Coutinho and coauthors present the prevalence and distribution of hereditary cerebellar ataxia and hereditary spastic paraplegia in Portugal.

SYSTEMIC METABOLIC ABNORMALITIES IN ADULT-ONSET ACID MALTASE DEFICIENCY

The possibility of other unidentified, systemic metabolic derangements that could contribute to the pathogenesis of glycogen storage disease type II is investigated by Pascual and Roe.

NEW SUBTYPE OF SPINOCEREBELLAR ATAXIA WITH ALTERED VERTICAL EYE MOVEMENTS MAPPING TO CHROMOSOME 1P32

In a family study, Serrano-Munuera and coauthors clinically and genetically characterize a Spanish kindred with pure spinocerebellar ataxia presenting with altered vertical eye movements.

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Road map to personal genome medicine. Since the completion of the human genome sequence in 2003, the research focus in human genetics has moved to how human genome variations affect human health. Human genome variations are considered to be associated not only with hereditary diseases but also with sporadic diseases. In addition, human genome variations are also associated with differences in drug responses and adverse effects. Optimization of treatment and prevention based on personal genome information will soon be a realistic paradigm in clinical practice.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

429 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs